Canada’s health regulator has approved Novo Nordisk’s weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said on Wednesday.
Trending
- Man arrested at LAX after allegedly checking suitcases filled with over 70 pounds of meth-caked clothing
- Hyundai recalling hundreds of thousands of cars and SUVs in Canada, U.S.
- Canada Post, union are ‘too far apart’ to reach a deal and end the strike: labour minister
- Police officer injured after being shot by fellow cop, B.C. RCMP say
- Toronto police identify infant victim of midtown homicide
- Trump picks Jay Bhattacharya, who backed COVID herd immunity, to lead National Institutes of Health
- More charges laid against pair involved in animal cruelty investigation: Winnipeg police
- American schools are bracing for upheaval over fear of mass deportations
Canada approves Novo Nordisk’s obesity drug to reduce risk of non-fatal heart attack
By
Add A Comment